Anthem Biosciences Ltd

- Anthem Biosciences has observed a healthy inflow of new inquiries and RFPs, indicating a strong order book pipeline. - The company mentions being ready with capacities (including Unit-III and upcoming Unit-IV) to service new RFPs over the next 2-3 years. - While exact pending order numbers are not disclosed, management is enthused by the steady flow of new good customers and inquiries. - The commissioning of Unit-III has already started generating revenues (~Rs. 55 Cr WIP), with plans to ramp this up to Rs. 100-150 Cr, supporting order execution. - The upcoming Unit-IV, expected to be commissioned in about two years, will further enhance capacity to handle increased orders, reflecting confidence in sustained order inflows. - Overall, Anthem expects consistent order growth to maintain around 20% CAGR over the next several years based on current trends.

- The transcript does not mention any current or planned fundraising through debt or equity. - The company has ongoing capital expenditures (CAPEX) for expansions, such as Rs. 350 Cr+ Rs. 100 Cr for Unit-III and Rs. 1,000 Cr for Unit-IV, but no specific funding sources are discussed. - There is no explicit indication of equity or debt issuance to fund these expansions in the provided discussion. - The management focuses on organic growth and capacity utilization rather than discussing new fundraising rounds. - Any future funding plans, if considered, were not disclosed in this transcript.

- Unit-IV: Rs. 1,000 Cr CAPEX planned for greenfield expansion with ~400 KL custom synthesis and ~100-200 KL fermentation capacity, expected to be commissioned within 2 years (by FY27-FY28). - Unit-III: Additional Rs. 100 Cr CAPEX to complete fermentation facilities by end of current year; limited further CAPEX expected afterward. - Unit-II: CP 6 and CP 7 expansions (~130 KL capacity) recently commissioned with Rs. 350 Cr plus Rs. 100 Cr CAPEX done; generating revenue potential of ~Rs. 300 Cr. - Focus on filling existing expanded capacities (Units II & III) before ramping up Unit-IV. - Replacement CAPEX expected to be minor, mainly on repairs and maintenance. - Continuous strategic investment in people training and capacity calibration aligned with revenue growth.

- Anthem Biosciences targets a compound annual growth rate (CAGR) of around 20% in revenue over the next several years, consistent with its past 10-15 years' performance. - Recent approval of 4 new commercial molecules is expected to drive growth, though some may be in pre-launch phases affecting immediate supply volumes. - Quarterly revenues may be lumpy due to fluctuating customer demand, but an overall upward trend is expected annually. - Existing molecules are growing robustly, with customers managing inventories carefully, which may temporarily affect volumes but growth remains strong. - Expansion projects (Unit-III and Unit-IV) and new capacities (e.g., 130 kiloliters added recently, Unit-IV with 400 kiloliters planned) aim to support increased volumes and revenues. - New product launches, including peptides and biologics, and collaborations with innovators are anticipated to contribute positively over the medium term. - While short-term funding uncertainties exist in biotech markets, Anthem’s strong sales funnel and customer base mitigate concerns on demand.

- Anthem Biosciences targets a revenue CAGR of approximately 20% over the next 5-10 years, consistent with its historical growth. - Short-term quarterly growth may be lumpy, with some quarters showing exceptional performance and others moderate, but a clear upward trend is expected. - Profit margins are anticipated to remain strong, with EBITDA margins aimed at the upper end of the 36%-37% range. - The company expects growth from new commercial molecules launched recently, though ramp-up may take time as customers plan product launches. - Expansion in capacities (Unit-III and Unit-IV) will drive future revenue, with Unit-III already generating Rs. 55 Cr WIP and expected to contribute Rs. 100-150 Cr in the near term. - Employee cost management and operational leverage are priorities to sustain margin expansion. - Overall, a healthy increase in EBITDA, PBT, PAT, and EPS is expected, aligned with revenue growth targets.